Scaling Up ADC Payloads
Webinar Date/Time: Thu, Oct 27, 2022 11:00 AM EDT
Join our latest webinar ‘Scaling up payload manufacturing for blockbuster ADCs.
Register free: https://www.pharmtech.com/pt_w/payloads
Event Overview:
Antibody-drug conjugates are a targeted approach to the treatment of cancer. As more of these complex products enter clinical development, the need to scale up production of their payloads becomes a pressing topic. In this webinar, participants will hear about Lonza’s investment in facilities capable of producing large quantities (100+ kg) under the strictest levels of containment.
- Market drivers
- Design concepts
- Facility overview
Key Learning Objectives:
- Key market trends
- Lonza’s approach to lifecycle investment
- Leadership in highly-potent API facility and process design
Who Should Attend:
- Key clients / potential clients from the ADC arena, covering all disciplines from biologics/ bioconjugation and payload-linker
Charles Johnson
Senior Director
Commercial Development
Lonza Small Molecules
Charles Johnson is the senior director of commercial development for Lonza Small Molecules. Charles has more than 20 years of experience in the pharmaceutical sector and specializes in antibody-drug conjugates. Prior to joining Lonza, Charles was CEO of ADC Biotechnology, which focuses on innovative immobilization technologies for protein conjugation and purification applications.
Register free: https://www.pharmtech.com/pt_w/payloads
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
